Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 1

Status

Completed 9Terminated 6Recruiting 5Withdrawn 3Active not recruiting 3Unknown 2Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6Thoracic 1Gynecologic 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 4Ovarian Neoplasms 3Neoplasms 2Fallopian Tube Neoplasms 2Triple Negative Metastatic Breast Cancer 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Pancreatic Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 78Capecitabine 59Cyclophosphamide 54Paclitaxel 52Docetaxel 50Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 26exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Taxes 17Everolimus 17Epirubicin 15pertuzumab 13Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13palbociclib 12Magnetic Resonance Spectroscopy 12liposomal doxorubicin 11atezolizumab 11Filgrastim 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × talazoparib × Clear all
NCT03901469 2025-10-07

TNBC

Zenith Epigenetics

Phase 2 Terminated
115 enrolled 31 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Hoosier Cancer Research Network

Phase 2 Terminated
52 enrolled 16 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04690855 2023-12-04

TARA

Hoosier Cancer Research Network

Phase 2 Terminated
1 enrolled 11 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03330405 2023-10-13

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Pfizer

Phase 1/2 Terminated
223 enrolled 50 charts
BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Recurrence

NCT03499353 2021-11-09

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Pfizer

Phase 2 Terminated
61 enrolled 63 charts
Breast

Breast Neoplasms

NCT02034916 2019-10-14

ABRAZO

Pfizer

Phase 2 Terminated
84 enrolled 21 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡